ASCO’s 2025 meeting emphasizes clinical trials and repurposing therapies, suggesting a future focused on patient-centered oncology.
THE 2025 American Society of Clinical Oncology (ASCO) Annual Meeting underscored a key principle: in today’s complex and rapidly evolving cancer landscape, the application of knowledge, not just its acquisition, is our most powerful tool for progress. Robin Zon’s presidential theme, “Driving Knowledge to Action: Building a Better Future,” was brought to life across the plenary sessions and data presentations that spanned tumor types, geographies, and therapeutic modalities. Two dominant motifs emerged from the most practice-changing studies: the use of large-scale, well-designed clinical trials to validate transformative interventions, and a growing effort to repurpose effective therapies earlier in the disease course, challenging historical treatment sequences. These principles reflect the essence of oncology’s future: evidence-powered, patient-centered, and accessible to all.
No takes yet. Share an insight, caveat, or question.
Ryan C. Augustin (2025) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: